Cargando…
P1222: PACIFIC: BRENTUXIMAB VEDOTIN AND NIVOLUMAB ALONE AND THEN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN AND PREDNISONE FOR UNTREATED PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA PATIENTS
Autores principales: | Steiner, R., Strati, P., Flowers, C., Neelapu, S., Green, M., Nastoupil, L., Hagemeister, F., Feng, L., Ahmed, S., Nair, R., Fayad, L., Lee, H., Rodriguez, M. A., Westin, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430250/ http://dx.doi.org/10.1097/01.HS9.0000847752.29527.f6 |
Ejemplares similares
-
The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study
por: Feng, Xiaomeng, et al.
Publicado: (2021) -
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas
por: Svoboda, Jakub, et al.
Publicado: (2020) -
Brentuximab Vedotin
Publicado: (2012) -
Brentuximab-vedotin/nivolumab: SARS-CoV-2 infection: case report
Publicado: (2020) -
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up
por: Zinzani, Pier Luigi, et al.
Publicado: (2023)